BioPharma Credit

BioPharma Credit FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of BioPharma Credit (BPCR.L) as of Nov 21, 2026 is 70.13 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 91.60 % — a change of -23.43% (lower).

FCF Conversion

70.13 %

YoY

-23.43%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of BioPharma Credit is 2025 70.13 % . FCF Conversion Rate (FCF/EBITDA) of BioPharma Credit was 2024 91.60 % . It decreases by -23.43% lower compared to the previous year.

The BioPharma Credit FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
95.71 USD
Jan 1, 2019
107.51 USD
Jan 1, 2020
65.15 USD
Jan 1, 2021
113.51 USD
Jan 1, 2022
101.08 USD
Jan 1, 2023
113.58 USD
Jan 1, 2024
91.60 USD
Jan 1, 2025
70.13 USD
The BioPharma Credit FCF Conversion history
YEARFCF ConversionYoY
70.13 %-23.43%
91.60 %-19.36%
113.58 %+12.37%
101.08 %-10.95%
113.51 %+74.23%
65.15 %-39.40%
107.51 %+12.33%
95.71 %+12.70%
84.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioPharma Credit Stock analysis

What does BioPharma Credit do? BioPharma Credit PLC was founded in 2017 and is an investment company specializing in financing in the biopharmaceutical and medical field. The company's goal is to identify investment opportunities in the rapidly growing biopharmaceutical market and generate lucrative returns for investors. BioPharma Credit's business model is based on providing loans to biotechnology and pharmaceutical companies. These loans are used to finance important projects and research that contribute to the development of new drugs and treatment methods. In return, the companies receive interest payments and loan repayments according to the agreements in the contract. BioPharma Credit pursues a differentiated strategy and invests in various sectors of the biopharmaceutical industry, such as cancer treatments, immunotherapies, or rare diseases. This includes riskier but potentially very profitable projects such as clinical trials or the market entry of new drugs. BioPharma Credit's portfolio currently includes approximately 26 investments in various areas of the biopharmaceutical industry. The company works closely with experienced partners such as the pharmaceutical company Pharmakia or the analysis firm IHS to conduct comprehensive due diligence and carefully assess opportunities and risks. Another important element of BioPharma Credit's business model is the investors. Most of BioPharma Credit's investors are institutional investors such as pension funds or insurance companies. Therefore, the company also takes into account the needs and requirements of these investors in the selection of borrowers and projects. BioPharma Credit offers its investors high transparency and protection against potential risks. All investments are made through a GmbH structure with fixed terms and fixed interest payments. In addition, the portfolio is regularly monitored and adjusted by an expert team to minimize risks and seize opportunities. Overall, BioPharma Credit offers its investors an attractive opportunity to benefit from the opportunities in the rapidly growing biopharmaceutical market without directly entering the risks and challenges of the biopharmaceutical industry. At the same time, BioPharma Credit contributes to driving important innovations and advancements in medicine and thereby generating societal and health benefits. One of BioPharma Credit's most successful investments in recent years, for example, was a loan to the British biotechnology company Orchard Therapeutics. This company specializes in the development of gene therapies for rare diseases. The loan from BioPharma Credit helped Orchard Therapeutics conduct a clinical trial and enter the market. Orchard Therapeutics' gene therapy has since been approved by the European Medicines Agency and has the potential to improve the lives of millions of people worldwide. Overall, the success story of BioPharma Credit demonstrates how investments in the field of biopharmaceuticals and medicine can contribute to driving important innovations and advancements in medicine while also achieving attractive returns for investors. The company has established itself as an experienced and reliable partner that, thanks to its expertise and networks, will continue to identify and realize successful investments in the biopharmaceutical sector in the future. BioPharma Credit is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioPharma Credit stock

FCF Conversion Rate (FCF/EBITDA) of BioPharma Credit is 70.13 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of BioPharma Credit changed from 91.60 % to 70.13 %, representing a -23.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) BioPharma Credit since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s BioPharma Credit with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioPharma Credit

All Key Metrics — BioPharma Credit